13F Holdings
中文EN

ENTX Entera Bio Ltd.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1638097 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-76.8%
TTM net income YoY-19.9%
TTM EPS YoY0.0%
Revenue 3-yr CAGR-32.1%
Net income 3-yr CAGR—

Margins

Gross margin0.0%
Operating margin-27,450.0%
Net margin-27,235.7%
FCF margin-17,802.4%
EBITDA margin-27,378.6%

Returns

ROE-108.0%
ROA-90.1%
ROIC (approx.)-341.6%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets18.1%
Debt / equity0.00x
Current ratio6.94x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.64x
Accruals ratio-32.1%
Payout ratio—
Capex / revenue254.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$42,000$181,000$0$134,000$571,000
Cost of revenue$42,000$172,000$0$101,000$373,000
Gross profit$0$9,000$0$33,000$198,000
R&D expense$6.00M$4.50M$4.51M$5.85M$6.77M
SG&A expense$398,000$340,000$4.43M$7.25M$5.69M
Operating income-$11.53M-$9.59M-$8.89M-$13.02M-$12.22M
Pretax income-$11.44M-$9.53M-$8.86M-$12.93M-$12.25M
Income tax$0$14,000$29,000$137,000-$59,000
Net income-$11.44M-$9.54M-$8.89M-$13.07M-$12.19M
EBITDA-$11.50M-$9.54M-$8.84M-$12.95M-$12.16M
EPS (basic)0.250.250.310.450.47
EPS (diluted)0.250.250.310.450.47
Weighted avg. shares (diluted)46.19M37.65M29.01M28.81M26.13M
Balance sheet
Cash & equivalents$7.11M$8.74M$11.09M$12.38M$24.96M
Receivables$0$126,000$0$246,000$183,000
Current assets$15.30M$8.97M$11.26M$12.85M$25.33M
PP&E, net$134,000$57,000$100,000$139,000$156,000
Total assets$15.99M$9.39M$11.77M$13.13M$25.99M
Current liabilities$2.20M$1.18M$1.09M$1.34M$3.16M
Total liabilities$2.89M$1.31M$1.38M$1.37M$3.42M
Shareholders' equity$13.10M$8.08M$10.39M$11.75M$22.57M
Shares outstanding46.18M38.84M35.48M28.81M28.80M
Cash flow statement
Operating cash flow-$7.37M-$6.82M-$7.31M-$12.50M-$9.06M
Capital expenditure$107,000$3,000$17,000$47,000$17,000
Free cash flow-$7.48M-$6.82M-$7.33M-$12.55M-$9.08M
Investing cash flow-$107,000-$3,000-$17,000-$102,000-$17,000
Financing cash flow$13.71M$4.48M$6.04M$13,000$25.38M
Depreciation & amortization$30,000$46,000$56,000$64,000$53,000
Stock-based compensation$2.75M$2.56M$1.69M$2.25M$1.86M

Free plan shows the latest 5 periods; Pro shows all 10 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.